Literature DB >> 25867763

Phenotypic diversity of patient-derived melanoma populations in stem cell medium.

Malgorzata Sztiller-Sikorska1, Mariusz L Hartman1, Beata Talar1, Justyna Jakubowska1, Izabela Zalesna1, Malgorzata Czyz1.   

Abstract

Melanomas are highly heterogeneous tumors and there is no treatment effective at achieving long-term remission for metastatic melanoma patients. Thus, an appropriate model system for studying melanoma biology and response to drugs is necessary. It has been shown that composition of the medium is a critical factor in preserving the complexity of the tumor in in vitro settings, and melanospheres maintained in stem cell medium are a good model in this respect. In the present study, we observed that not all nodular melanoma patient-derived cell populations grown in stem cell medium were capable of forming melanospheres, and cell aggregates and anchorage-independent single-cell cultures emerged instead. Self-renewing capacity and unlimited growth potential indicated the presence of cells with stem-like properties in all patient-derived populations but immunophenotype and MITF expression exhibited variability. Enhanced MITF expression and activity was observed in melanospheres in comparison with cell aggregates and single-cell culture, and hypoxic-like conditions that increased the ability of single-cell population to form melanospheres enhanced MITF expression and cell pigmentation as well. Thus, MITF seems to be a critical transcription factor for formation of both patient-derived and hypoxia-induced melanospheres. After 2 years of continuous culturing, melanospheres progressively underwent transition into cell aggregates that was accompanied by changes in expression of several MITF-dependent genes associated with melanogenesis and survival and alterations in the composition of subpopulations but not in the frequency of ABCB5-positive cells. Several biological properties of parent tumor are well preserved in patient-derived melanospheres, but during prolonged culturing the heterogeneity is substantially lost when the melanospheres are substituted by cell aggregates. This should be considered when cell aggregates instead of melanospheres are used in the study of melanoma biology and cell response to drugs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25867763     DOI: 10.1038/labinvest.2015.48

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  73 in total

1.  Increased expression of stem cell markers in malignant melanoma.

Authors:  Walter M Klein; Bryan P Wu; Shuping Zhao; Hong Wu; Andres J P Klein-Szanto; Steven R Tahan
Journal:  Mod Pathol       Date:  2006-11-24       Impact factor: 7.842

2.  Parthenolide enhances dacarbazine activity against melanoma cells.

Authors:  Kamila Koprowska; Mariusz L Hartman; Malgorzata Sztiller-Sikorska; Malgorzata E Czyz
Journal:  Anticancer Drugs       Date:  2013-09       Impact factor: 2.248

3.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

4.  Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo.

Authors:  Susann Peickert; Julia Waurig; Claudia Dittfeld; Antje Dietrich; Yvette Garbe; Lydia Kabus; Michael Baumann; Marian Grade; Thomas Ried; Leoni A Kunz-Schughart
Journal:  Lab Invest       Date:  2012-09-10       Impact factor: 5.662

5.  Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Authors:  Mark Shackleton; Elsa Quintana; Eric R Fearon; Sean J Morrison
Journal:  Cell       Date:  2009-09-04       Impact factor: 41.582

Review 6.  Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century.

Authors:  Samuel A Williams; Wade C Anderson; Marianne T Santaguida; Scott J Dylla
Journal:  Lab Invest       Date:  2013-08-05       Impact factor: 5.662

7.  The in-vitro spheroid culture induces a more highly differentiated but tumorigenic population from melanoma cell lines.

Authors:  Jing Mo; Baocun Sun; Xiulan Zhao; Qiang Gu; Xueyi Dong; Zhiyong Liu; Yuemei Ma; Nan Zhao; Yanrong Liu; Jiadong Chi; Ran Sun
Journal:  Melanoma Res       Date:  2013-08       Impact factor: 3.599

8.  CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133- cells.

Authors:  Celia Chao; J Russ Carmical; Kirk L Ives; Thomas G Wood; Judith F Aronson; Guillermo A Gomez; Clarisse D Djukom; Mark R Hellmich
Journal:  Lab Invest       Date:  2011-12-12       Impact factor: 5.662

9.  Functional features of cancer stem cells in melanoma cell lines.

Authors:  Rüdiger M Zimmerer; Philippe Korn; Philippe Demougin; Andreas Kampmann; Horst Kokemüller; André M Eckardt; Nils-Claudius Gellrich; Frank Tavassol
Journal:  Cancer Cell Int       Date:  2013-08-06       Impact factor: 5.722

10.  Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions.

Authors:  Caroline N Mills; Sandeep S Joshi; Richard M Niles
Journal:  Mol Cancer       Date:  2009-11-17       Impact factor: 27.401

View more
  13 in total

1.  Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.

Authors:  Mariusz L Hartman; Michal Rozanski; Marta Osrodek; Izabela Zalesna; Malgorzata Czyz
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

2.  MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment.

Authors:  Mariusz L Hartman; Beata Talar; Anna Gajos-Michniewicz; Malgorzata Czyz
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

3.  Pentoxifylline Inhibits WNT Signalling in β-Cateninhigh Patient-Derived Melanoma Cell Populations.

Authors:  Beata Talar; Anna Gajos-Michniewicz; Marcin Talar; Salem Chouaib; Malgorzata Czyz
Journal:  PLoS One       Date:  2016-06-28       Impact factor: 3.240

4.  Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro.

Authors:  Izabela Zalesna; Marta Osrodek; Mariusz L Hartman; Michal Rozanski; Malgorzata Sztiller-Sikorska; Karolina Niewinna; Dariusz Nejc; Malgorzata Czyz
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

5.  PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.

Authors:  Małgorzata Czyż; Monika Toma; Anna Gajos-Michniewicz; Kinga Majchrzak; Grazyna Hoser; Janusz Szemraj; Margaret Nieborowska-Skorska; Phil Cheng; Daniel Gritsyuk; Mitchell Levesque; Reinhard Dummer; Tomasz Sliwinski; Tomasz Skorski
Journal:  Oncotarget       Date:  2016-11-15

6.  17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes.

Authors:  Aleksandra Mielczarek-Lewandowska; Malgorzata Sztiller-Sikorska; Marta Osrodek; Malgorzata Czyz; Mariusz L Hartman
Journal:  Apoptosis       Date:  2019-08       Impact factor: 4.677

7.  Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.

Authors:  Mariusz L Hartman; Malgorzata Sztiller-Sikorska; Anna Gajos-Michniewicz; Malgorzata Czyz
Journal:  Cells       Date:  2020-01-07       Impact factor: 6.600

8.  Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.

Authors:  Mariusz L Hartman; Beata Talar; Malgorzata Sztiller-Sikorska; Dariusz Nejc; Malgorzata Czyz
Journal:  Oncotarget       Date:  2016-02-23

Review 9.  Intratumor and Intertumor Heterogeneity in Melanoma.

Authors:  Tomasz M Grzywa; Wiktor Paskal; Paweł K Włodarski
Journal:  Transl Oncol       Date:  2017-10-24       Impact factor: 4.243

10.  17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines.

Authors:  Mariusz L Hartman; Magdalena Rogut; Aleksandra Mielczarek-Lewandowska; Michal Wozniak; Malgorzata Czyz
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.